Stockscreener 앱 받기
350.78
0.08%
0.29
전일 마감가:
$350.49
열려 있는:
$349.99
하루 거래량:
3.29M
Relative Volume:
4.92
시가총액:
$13.74B
수익:
$1.24B
순이익/손실:
$42.23M
주가수익비율:
330.92
EPS:
1.06
순현금흐름:
$150.33M
1주 성능:
+8.79%
1개월 성능:
+13.85%
6개월 성능:
+49.64%
1년 성능:
+33.73%
1일 변동 폭
$349.12
$352.07
1주일 범위
$290.00
$352.15
52주 변동 폭
$221.26
$352.15
Penumbra Inc Stock (PEN) Company Profile
명칭
Penumbra Inc
전화
(510) 995-2486
주소
ONE PENUMBRA PLACE, ALAMEDA, CA
PEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
350.78 | 13.73B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-11-18 | 개시 | Wells Fargo | Underweight |
| 2025-10-08 | 업그레이드 | Needham | Hold → Buy |
| 2025-09-02 | 개시 | Evercore ISI | Outperform |
| 2025-03-14 | 개시 | BofA Securities | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-12-17 | 개시 | Oppenheimer | Outperform |
| 2024-12-11 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | 개시 | Stifel | Buy |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-31 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-03-29 | 다운그레이드 | Needham | Buy → Hold |
| 2023-01-30 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-10-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-09-09 | 업그레이드 | Needham | Hold → Buy |
| 2022-07-18 | 개시 | RBC Capital Mkts | Outperform |
| 2022-04-19 | 개시 | Deutsche Bank | Buy |
| 2022-03-08 | 개시 | Needham | Hold |
| 2021-09-16 | 개시 | Truist | Buy |
| 2021-06-04 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-10-07 | 재개 | Canaccord Genuity | Buy |
| 2020-09-29 | 개시 | BTIG Research | Buy |
| 2020-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-05-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-05-21 | 개시 | William Blair | Outperform |
| 2018-10-29 | 재개 | BofA/Merrill | Buy |
| 2018-10-08 | 개시 | RBC Capital Mkts | Outperform |
| 2018-02-21 | 개시 | William Blair | Outperform |
| 2018-01-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-11-30 | 재확인 | Canaccord Genuity | Buy |
| 2015-10-13 | 개시 | Wells Fargo | Outperform |
모두보기
Penumbra Inc 주식(PEN)의 최신 뉴스
Penumbra Shares Soar Pre-MarketWhat Is The Boston Scientific Agreement? - Menafn
Halper Sadeh LLC Encourages PEN, CVGW, AVO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
(PEN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
US-based Penumbra preliminary revenue up 22% Q4 2025 - Medical Buyer
Boston Scientific to acquire Penumbra for $14.5 billion By Investing.com - Investing.com Nigeria
RTW Biotech Opp.Boston Scientific to acquire Penumbra - Research Tree
Penumbra (PEN) Receives Neutral Rating with Raised Price Target by Citigroup | PEN Stock News - GuruFocus
PEN: Baird Downgrades Penumbra to 'Neutral', Raises Price Target - GuruFocus
PEN: Truist Securities Downgrades Penumbra to Hold | PEN Stock N - GuruFocus
Penumbra stock hits 52-week high at $321.47 By Investing.com - Investing.com Nigeria
Penumbra Inc. to be Sold to Boston Scientific for $374 per Share - Intellectia AI
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc.PEN - Your Wyoming Link
Penumbra Announces Strong Preliminary Revenue Growth for 2025 - The Globe and Mail
Boston Scientific to acquire Penumbra in $14.5 billion deal - DOTmed
Penumbra (PEN) Climbs to All-Time High on $14.5-Billion Merger - Insider Monkey
PEN Downgraded to Hold by Jefferies; Price Target Raised | PEN S - GuruFocus
Penumbra (PEN) Downgraded to Market Perform by Leerink Partners - GuruFocus
PEN Downgraded to Hold by Needham's Analyst Mike Matson | PEN St - GuruFocus
Needham & Company LLC Reaffirms "Hold" Rating for Penumbra (NYSE:PEN) - MarketBeat
Truist Securities Downgrades Penumbra to Hold From Buy, Adjusts PT to $374 From $370 - marketscreener.com
Analyst Expectations For Penumbra's Future - Benzinga
Citigroup Downgrades Penumbra to Neutral From Buy, Adjusts Price Target to $374 From $350 - marketscreener.com
Boston Scientific: Adding Another Growth Engine With Penumbra (NYSE:BSX) - Seeking Alpha
Boston Scientific announces agreement to acquire Penumbra, Inc. - Med-Tech Insights
This JM Smucker Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Penumbra (PEN) Moves 11.8% Higher: Will This Strength Last? - Yahoo Finance
Published on: 2026-01-16 16:12:24 - baoquankhu1.vn
Truist Securities downgrades Penumbra stock to Hold following Boston Scientific acquisition - Investing.com Australia
Boston Scientific to acquire Penumbra for $14.5 billion - Investing.com India
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results - BioSpace
RTW Biotech Opportunities Portfolio Company Penumbra To Be Acquired By Boston Scientific - DirectorsTalk Interviews
Penumbra reports preliminary Q4 revenue growth of over 21% By Investing.com - Investing.com Nigeria
Boston Scientific to acquire Penumbra in $14.5 billion deal By Investing.com - Investing.com Nigeria
Boston Scientific Set to Acquire Penumbra in $14.5 Billion Deal to Expand Vascular Therapy Offerings - Hoodline
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead - TechStock²
Penumbra (PEN) Downgraded to Market Perform by William Blair | P - GuruFocus
Boston Scientific to acquire Penumbra for portfolio of vascular treatments - MLex
Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next - TechStock²
[425] Penumbra Inc Business Combination Communication | PEN SEC FilingForm 425 - Stock Titan
Penumbra’s Stock Set to Surge Amid New Price Targets - timothysykes.com
Boston Sci swings for the fences with $14.5B Penumbra buy - BioWorld MedTech
Fenwick Represents Perella Weinberg Partners in Penumbra's $14.5B Acquisition by Boston Scientific - fenwick.com
One of Alameda's largest companies agrees to be acquired for $14.5 billion - The Business Journals
Penumbra’s Bright Future: Analysts Raise Price Targets as MedTech Sector Rebounds - StocksToTrade
Penumbra (PEN) Downgraded by Wells Fargo to Equal-Weight | PEN S - GuruFocus
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Penumbra, Inc. (NYSE: PEN) - PR Newswire
Penumbra (PEN) Shares Surge Nearly 12% - GuruFocus
Penumbra Shares Buoyed by Analyst Upgrades and Market Positivity - timothysykes.com
Penumbra (PEN) Projects 67.1% Gross Margin for Fiscal Year 2025 - GuruFocus
Boston Scientific Catches Lightning in a Bottle with Penumbra - Medical Device and Diagnostic industry
Why Penumbra (PEN) Stock Is Trading Up Today - Finviz
Penumbra Inc (PEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
1.96%
자본화:
|
볼륨(24시간):